Vertex Announces Departure of Ian Smith, Names Interim CFO
“At Vertex, we are deeply committed to our culture of diversity, inclusion and respect, and we insist that all of our employees, regardless of their seniority, live our values and adhere to our Code of Conduct,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “This decision was not related to any conduct concerning the company's operations or finances.”
“Vertex has a strong management team in place, as well as a deep bench. In 2019 and beyond, I am confident that we will continue to successfully execute the company’s long-standing strategy to bring transformative treatments to all people living with cystic fibrosis (CF) and advance our diverse pipeline of medicines for other serious diseases,” Leiden continued. “Making a difference in the lives of patients, their families and their caregivers is our true north, and our commitment to this ideal is unwavering.”
As previously announced, Vertex will report its fourth quarter and full
year 2018 financial results after the financial markets close on
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in
Michael Partridge, 617-341-6108